fashion -WSS

fashion

author：comprehensive 2025-10-02 00:52:40 - browse：99

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why 40% Americans with Parkinson’s don’t see a neurologist

WSS

Lecanemab for Alzheimer's is coming. Is the health system ready?

Beach reads and more: STAT's 2023 summer book list

Why 40% Americans with Parkinson’s don’t see a neurologist

The Sacklers, horror, and ‘The Fall of the House of Usher’

Sanofi CEO defends move to abandon profit guidance, boost research

Charles Manson follower Leslie Van Houten released from prison after 53 years

Wikipedia

fashion

hotspot

In age of alternative facts, a scholarly course on calling out crap

FDA approves Recor Medical high blood pressure device

How one medical school became remarkably diverse

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Moonlake's readout produced a cash windfall. Risks remain

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Medical records are filled with copy

Biden launches a new push to limit health care costs

knowledge

UCSF medical school apologizes for unethical prisoner experiments

Extreme heat events are a public health emergency

HCA discloses massive data breach affecting 11 million patients

MoonLake credibility takes another hit with mid

NIH fellows want a pay raise. Will that mean less money for grants?

UCSF medical school apologizes for unethical prisoner experiments

entertainment

hotspot

knowledge

explore